1. Home
  2. XOMAP vs OBE Comparison

XOMAP vs OBE Comparison

Compare XOMAP & OBE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMAP
  • OBE
  • Stock Information
  • Founded
  • XOMAP N/A
  • OBE 1979
  • Country
  • XOMAP United States
  • OBE Canada
  • Employees
  • XOMAP 13
  • OBE N/A
  • Industry
  • XOMAP Biotechnology: Pharmaceutical Preparations
  • OBE Oil & Gas Production
  • Sector
  • XOMAP Health Care
  • OBE Energy
  • Exchange
  • XOMAP Nasdaq
  • OBE Nasdaq
  • Market Cap
  • XOMAP N/A
  • OBE N/A
  • IPO Year
  • XOMAP N/A
  • OBE N/A
  • Fundamental
  • Price
  • XOMAP $26.04
  • OBE $4.99
  • Analyst Decision
  • XOMAP
  • OBE Buy
  • Analyst Count
  • XOMAP 0
  • OBE 2
  • Target Price
  • XOMAP N/A
  • OBE $11.50
  • AVG Volume (30 Days)
  • XOMAP N/A
  • OBE 440.2K
  • Earning Date
  • XOMAP N/A
  • OBE 05-07-2025
  • Dividend Yield
  • XOMAP N/A
  • OBE N/A
  • EPS Growth
  • XOMAP N/A
  • OBE N/A
  • EPS
  • XOMAP N/A
  • OBE N/A
  • Revenue
  • XOMAP N/A
  • OBE $525,689,636.00
  • Revenue This Year
  • XOMAP N/A
  • OBE N/A
  • Revenue Next Year
  • XOMAP N/A
  • OBE $8.69
  • P/E Ratio
  • XOMAP N/A
  • OBE N/A
  • Revenue Growth
  • XOMAP N/A
  • OBE 15.98
  • 52 Week Low
  • XOMAP N/A
  • OBE $3.88
  • 52 Week High
  • XOMAP N/A
  • OBE $7.87
  • Technical
  • Relative Strength Index (RSI)
  • XOMAP 59.38
  • OBE 56.66
  • Support Level
  • XOMAP $25.41
  • OBE $4.77
  • Resistance Level
  • XOMAP $26.18
  • OBE $5.04
  • Average True Range (ATR)
  • XOMAP 0.14
  • OBE 0.18
  • MACD
  • XOMAP 0.05
  • OBE 0.04
  • Stochastic Oscillator
  • XOMAP 82.16
  • OBE 68.33

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Share on Social Networks: